A Randomised, Single-Blind, Placebo-Controlled, Single-Centre Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After High Single Ascending Oral Supratherapeutic Doses of AZD1656 in Male Type 2 Diabetes Mellitus (T2DM) Patients.
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2011
At a glance
- Drugs AZD 1656 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 16 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Oct 2010 Status changed from not yet recruiting to recruiting, based on information from ClinicalTrials.gov.
- 21 Oct 2010 New trial record